<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121145</url>
  </required_header>
  <id_info>
    <org_study_id>Ty21a-ASC</org_study_id>
    <nct_id>NCT02121145</nct_id>
  </id_info>
  <brief_title>Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines</brief_title>
  <acronym>Ty21a-ASC</acronym>
  <official_title>Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a recent controlled study, the investigators explored cross-reactive immune responses
      against different Salmonella spp. in healthy volunteers immunized with either the oral
      (Vivotif® ) or parenteral (Typherix®) typhoid vaccines (ISRCTN68125331). In the present study
      immune responses will be studied in a group receiving both of these vaccines and in the
      previously immunized volunteers after booster immunization (same groups receive same vaccines
      2-4 years after primary immunization).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many Salmonella spp causing gastroenteritis share O antigen serotypes with Salmonella
      enteritidis subsp. enterica serovar Typhi (S.typhi) and could therefore be in 'reach' of the
      protective efficacy of the oral live typhoid fever vaccine Vivotif®. Some of these
      Salmonellae are common causes of diarrhoea in travellers (0-30% of travellers diarrhea
      depending on the area). In a recent controlled study, the investigators showed that a
      cross-reactive immune response is elicited against different Salmonella spp. in healthy
      volunteers immunized with either the oral (Vivotif® ) or parenteral (Typherix®) typhoid
      vaccines (ISRCTN68125331).

      In the present study immune responses will be studied in a group receiving both of these
      vaccines and in previously immunized volunteers after booster immunization (same groups
      receive same vaccines 2-4 years after primary immunization; groups: Vivotif / Typherix /
      Vivotif + Typherix). The results are compared to those obtained after primary immunization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of circulating plasmablasts specific to various Salmonella strains</measure>
    <time_frame>7 days</time_frame>
    <description>To study whether cross-reactive immune response is similar
if the two vaccines are given simultaneously
after booster immunization than after primary immunization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of serum antibodies specific to various Salmonella strains</measure>
    <time_frame>28 days</time_frame>
    <description>To study whether cross-reactive serum immune response is similar
if the two vaccines are given simultaneously
after booster immunization than after primary immunization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Record adverse effects of the vaccines used</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vivotif + Typherix primary immunization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vivotif + Typherix primary immunization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vivotif booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typherix booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vivotif + Typherix booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vivotif</intervention_name>
    <description>3 oral doses</description>
    <arm_group_label>Vivotif + Typherix primary immunization</arm_group_label>
    <arm_group_label>Vivotif booster</arm_group_label>
    <arm_group_label>Vivotif + Typherix booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typherix</intervention_name>
    <description>one intramuscular dose</description>
    <arm_group_label>Vivotif + Typherix primary immunization</arm_group_label>
    <arm_group_label>Typherix booster</arm_group_label>
    <arm_group_label>Vivotif + Typherix booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged ≥18 to ≤65 years

          2. General good health as established by medical history and physical examination

          3. Written informed consent

          4. Females of childbearing potential must agree to use an efficacious hormonal or barrier
             method of birth control during the study. Abstinence is acceptable.

          5. Available for all visits scheduled in this study.

        Exclusion Criteria:

          1. Primary groups: Vaccination against typhoid fever within 5 years before dosing.

          2. History of clinical typhoid fever, clinical paratyphoid A or B fever.

          3. Immunization with any other vaccine (oral or parenteral) within 4 weeks prior to study
             start or planned vaccination during the study

          4. Current intake of antibiotics or end of antibiotic therapy &lt;8 days before first IMP
             administration

          5. Chronic (longer than 14 days) administration of immunosuppressants or other
             immune-modifying drugs within 6 months before the first dose of investigational
             vaccine; oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent
             are excluded; inhaled or topical steroids are allowed

          6. Acute or chronic clinically significant gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anu Kantele, Assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Kantele, Assoc. prof.</last_name>
    <phone>+358503097640</phone>
    <email>anu.kantele@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sari H Pakkanen, MSc</last_name>
    <phone>+358405166165</phone>
    <email>sari.pakkanen@helsinki.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Helsinki, Haartman Institute</name>
      <address>
        <city>Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aava Medical Centre</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuija Oksanen, Nurse</last_name>
      <email>tuija.oksanen@aava.fi</email>
    </contact>
    <investigator>
      <last_name>Anu Kantele, Assoc. prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>April 19, 2014</last_update_submitted>
  <last_update_submitted_qc>April 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Anu Kantele</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Vivotif</keyword>
  <keyword>Typherix</keyword>
  <keyword>Salmonella Typhi</keyword>
  <keyword>non-typhoid Salmonella</keyword>
  <keyword>Salmonella Paratyphi</keyword>
  <keyword>enzyme-linked immunospot assay</keyword>
  <keyword>Plasmablast</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

